194 related articles for article (PubMed ID: 7923219)
1. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells.
Monsky WL; Lin CY; Aoyama A; Kelly T; Akiyama SK; Mueller SC; Chen WT
Cancer Res; 1994 Nov; 54(21):5702-10. PubMed ID: 7923219
[TBL] [Abstract][Full Text] [Related]
2. The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
Mori Y; Kono K; Matsumoto Y; Fujii H; Yamane T; Mitsumata M; Chen WT
Oncology; 2004; 67(5-6):411-9. PubMed ID: 15713998
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro.
Yamamoto M; Mohanam S; Sawaya R; Fuller GN; Seiki M; Sato H; Gokaslan ZL; Liotta LA; Nicolson GL; Rao JS
Cancer Res; 1996 Jan; 56(2):384-92. PubMed ID: 8542596
[TBL] [Abstract][Full Text] [Related]
4. Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers.
Kelly T; Kechelava S; Rozypal TL; West KW; Korourian S
Mod Pathol; 1998 Sep; 11(9):855-63. PubMed ID: 9758365
[TBL] [Abstract][Full Text] [Related]
5. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas.
Airola K; Karonen T; Vaalamo M; Lehti K; Lohi J; Kariniemi AL; Keski-Oja J; Saarialho-Kere UK
Br J Cancer; 1999 May; 80(5-6):733-43. PubMed ID: 10360651
[TBL] [Abstract][Full Text] [Related]
6. Spectrum of extracellular matrix degrading enzymes in normal and malignant T lymphocytes.
Hauzenberger D; Bergström SE; Klominek J; Sundqvist KG
Anticancer Res; 1999; 19(3A):1945-52. PubMed ID: 10470139
[TBL] [Abstract][Full Text] [Related]
7. Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton.
Artym VV; Kindzelskii AL; Chen WT; Petty HR
Carcinogenesis; 2002 Oct; 23(10):1593-601. PubMed ID: 12376466
[TBL] [Abstract][Full Text] [Related]
8. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
9. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease.
Piñeiro-Sánchez ML; Goldstein LA; Dodt J; Howard L; Yeh Y; Tran H; Argraves WS; Chen WT
J Biol Chem; 1997 Mar; 272(12):7595-601. PubMed ID: 9065413
[TBL] [Abstract][Full Text] [Related]
10. An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation.
Bowden ET; Barth M; Thomas D; Glazer RI; Mueller SC
Oncogene; 1999 Aug; 18(31):4440-9. PubMed ID: 10442635
[TBL] [Abstract][Full Text] [Related]
11. A matrix metalloproteinase expressed on the surface of invasive tumour cells.
Sato H; Takino T; Okada Y; Cao J; Shinagawa A; Yamamoto E; Seiki M
Nature; 1994 Jul; 370(6484):61-5. PubMed ID: 8015608
[TBL] [Abstract][Full Text] [Related]
12. Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells.
Yamaguchi H; Takeo Y; Yoshida S; Kouchi Z; Nakamura Y; Fukami K
Cancer Res; 2009 Nov; 69(22):8594-602. PubMed ID: 19887621
[TBL] [Abstract][Full Text] [Related]
13. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography.
Kurschat P; Wickenhauser C; Groth W; Krieg T; Mauch C
J Pathol; 2002 Jun; 197(2):179-87. PubMed ID: 12015741
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma.
Qin H; Moellinger JD; Wells A; Windsor LJ; Sun Y; Benveniste EN
J Immunol; 1998 Dec; 161(12):6664-73. PubMed ID: 9862695
[TBL] [Abstract][Full Text] [Related]
15. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).
Gilmore BF; Lynas JF; Scott CJ; McGoohan C; Martin L; Walker B
Biochem Biophys Res Commun; 2006 Jul; 346(2):436-46. PubMed ID: 16769036
[TBL] [Abstract][Full Text] [Related]
16. Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion.
Schnaeker EM; Ossig R; Ludwig T; Dreier R; Oberleithner H; Wilhelmi M; Schneider SW
Cancer Res; 2004 Dec; 64(24):8924-31. PubMed ID: 15604254
[TBL] [Abstract][Full Text] [Related]
17. MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment.
Bérubé M; Deschambeault A; Boucher M; Germain L; Petitclerc E; Guérin SL
Mol Vis; 2005 Dec; 11():1101-11. PubMed ID: 16379022
[TBL] [Abstract][Full Text] [Related]
18. Expression of seprase in effusions from patients with epithelial ovarian carcinoma.
Zhang MZ; Qiao YH; Nesland JM; Trope C; Kennedy A; Chen WT; Suo ZH
Chin Med J (Engl); 2007 Apr; 120(8):663-8. PubMed ID: 17517181
[TBL] [Abstract][Full Text] [Related]
19. Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Goscinski MA; Suo ZH; Nesland JM; Chen WT; Zakrzewska M; Wang J; Zhang S; Flørenes VA; Giercksky KE
Oncology; 2008; 75(1-2):49-59. PubMed ID: 18787344
[TBL] [Abstract][Full Text] [Related]
20. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness.
Ginestra A; La Placa MD; Saladino F; Cassarà D; Nagase H; Vittorelli ML
Anticancer Res; 1998; 18(5A):3433-7. PubMed ID: 9858920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
